Fesko John sold $700K of NTRA

Fesko John (PRESIDENT, CHIEF BUS. OFFICER) sold 1,679 shares of Natera, Inc. (NTRA) at an average of $416.88 ($406.00–$426.34, $0.70M total) across 2 trades over 2026-10-27 to 2026-10-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fesko John
Published Oct 30, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 2:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Bearish
medium confidence
Mentioned
$NTRA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRABearishMed
01

Why it matters

The disclosed sale provides fresh data on insider sentiment, potentially influencing short‑term price action.

02

Market read

First‑report insider sale of a senior executive, modest size but notable for market participants.

03

What to watch

The insider retained a large position of 195,578 shares, indicating continued confidence.

Relevance 4/10Novelty 7/10Timing: after-hours

Background

SEC Form 4 filing reports an insider transaction by Natera's President and COO.

Company-level read

Ticker impact

$NTRABearishMedium confidence
Context

President and COO of Natera sold 1,679 shares for $699,939.68 via a 10b5-1 plan.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

The insider holds a senior executive role and sold nearly $700k of stock, which can prompt short‑term downside sentiment.

Market effects

May raise concerns about Natera's outlook and could weigh on biotech sector sentiment.

US equity market may see modest negative pressure on related biotech stocks.

Limited to investors tracking US biotech companies.

Counterpoint

The sale could be a routine 10b5‑1 execution unrelated to company fundamentals.

Key entities

  • Natera, Inc.

    Biotech firm developing non‑invasive prenatal testing.

  • Fesko John

    President and Chief Business Officer of Natera.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.